News about Global Pharma

PANTHERx Rare Collaborates with Gilead Sciences for Distribution of LIVDELZI

LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

Global Pharma | 17/08/2024 | By Aishwarya |  309

Hoth Therapeutics Signs Deal with Aronnax for HT-KIT Cancer Therapeutic

Hoth Therapeutics has signed a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.

Global Pharma | 16/08/2024 | By Aishwarya |  531

Blue Earth Therapeutics Expands Partnership Deal with Seibersdorf Labor

Blue Earth Therapeutics Ltd. has expanded its manufacturing agreements with Seibersdorf Labor GmbH to include the manufacture of its investigational 225Ac-based radioligand therapy.

Global Pharma | 16/08/2024 | By Aishwarya |  526

Alembic Pharmaceuticals Gets FDA Approval for Dabigatran Etexilate Capsules

Dabigatran Etexilate Capsules 110 mg are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. Refer label for a detailed indication.

Global Pharma | 16/08/2024 | By Aishwarya |  695

Lobe Sciences Establishes Wholly Owned Subsidiary Alera Pharma

Alera will be assigned the intellectual property rights focused on the company’s neurological assets and its new chemical entity Psilocin Mucate.

Global Pharma | 16/08/2024 | By Aishwarya |  864

Wanbury Appoints Prakash Venkatraman as President of API Business

Wanbury Ltd. has appointed Prakash Venkatraman as President of the API business.

Global Pharma | 14/08/2024 | By Aishwarya |  523

Merck to Acquire CN201 from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Global Pharma | 14/08/2024 | By Aishwarya |  390

Persist AI and Nivagen to Develop AI-Driven Manufacturing Process for LAI Drugs

The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.

Global Pharma | 13/08/2024 | By Aishwarya |  585

Champalimaud Foundation to Leverage Lonza Platform to Advance Cell Therapy

Champalimaud Foundation, a biomedical clinical research organization carrying out research and cutting-edge clinical development and discoveries that benefit people, and Lonza have announced the installation of Lonza’s MODA-ES Platform at the Champalimaud Clinical Centre in Lisbon, Portugal.

Global Pharma | 13/08/2024 | By Aishwarya |  776

Biosyngen Gets FDA Approval for BRG01 for Phase II Clinical Trial

Biosyngen has announced that the US Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.

Global Pharma | 13/08/2024 | By Aishwarya |  476